Actavis Expands Manufacturing Operations in Puerto Rico - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Actavis Expands Manufacturing Operations in Puerto Rico



The Puerto Rico Industrial Development Company (PRIDCo) and Actavis announced that the company will develop a solid dosage manufacturing and packing facility at its Manati site and expand its current hormone production in Fajardo.

Actavis is investing $48 million and has committed to create up to 300 new jobs over a 36-month period; it has already has created 100 jobs. The investment will allow the company to bring new lines of generic, brand, and biosimilar products. When the expansion is completed, Actavis will have 700 employees in Puerto Rico.

All plans are expected to be complete by 2016.

Source: Puerto Rico Industrial Development Company

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here